Stem cell allograft recipient characteristics
| Patient . | HLA type . | Age/sex . | Diagnosis . | Conditioning . | |
|---|---|---|---|---|---|
| Donor . | Recipient . | ||||
| A | A3,32; B8,35 | Same | 50/M | NHL | BEAM |
| B | A1,2; B44,51 | Same | 32/F | NHL | TBI/CY |
| C | A1,2; B8,44 | Same | 31/M | NKL | TBI/CY |
| D | A2,11; B27,52 | Same | 29/F | AML | TBI/CY |
| E | A2,28; B37,44 | Same | 38/F | NHL | BU/CY |
| F | A11,23; B49,— | A2,23; B49,60 | 49/M | ALL | TBI/CY/ATG/TCD |
| M-1 | A2,74; B35,70 | A2,30; B35,70 | 47/F | CML | TBI/CY/ATG |
| M-2 | A3,—; B60,62 | A3,—; B7,40 | 9/F | ALL | TBI/CY/ATG |
| M-3 | A2,—; B56,57 | A2,—; B18,57 | 49/M | MDS | TBI/CY/ATG |
| M-4 | A24,—; B7,56 | A24,—; B7,56 | 52/M | AML | TBI/CY |
| M-5 | A1,2; B15,— | A2,32; B15,— | 19/F | ALL | TBI/CY/ATG |
| Patient . | HLA type . | Age/sex . | Diagnosis . | Conditioning . | |
|---|---|---|---|---|---|
| Donor . | Recipient . | ||||
| A | A3,32; B8,35 | Same | 50/M | NHL | BEAM |
| B | A1,2; B44,51 | Same | 32/F | NHL | TBI/CY |
| C | A1,2; B8,44 | Same | 31/M | NKL | TBI/CY |
| D | A2,11; B27,52 | Same | 29/F | AML | TBI/CY |
| E | A2,28; B37,44 | Same | 38/F | NHL | BU/CY |
| F | A11,23; B49,— | A2,23; B49,60 | 49/M | ALL | TBI/CY/ATG/TCD |
| M-1 | A2,74; B35,70 | A2,30; B35,70 | 47/F | CML | TBI/CY/ATG |
| M-2 | A3,—; B60,62 | A3,—; B7,40 | 9/F | ALL | TBI/CY/ATG |
| M-3 | A2,—; B56,57 | A2,—; B18,57 | 49/M | MDS | TBI/CY/ATG |
| M-4 | A24,—; B7,56 | A24,—; B7,56 | 52/M | AML | TBI/CY |
| M-5 | A1,2; B15,— | A2,32; B15,— | 19/F | ALL | TBI/CY/ATG |
M indicates male; F, female; NHL, non-Hodgkin lymphoma; AML, acute myeloid leukemia; NKL, natural killer cell lymphoma; —, no other allele detected; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; BEAM, BCNU, etoposide, ara-C, and melphalan; TBI, total body irradiation; CY, cytoxan; ATG, antithymocyte globulin; and TCD, T-cell depletion.